Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phentermine/topiramate - VIVUS

Drug Profile

Phentermine/topiramate - VIVUS

Alternative Names: Phentermine and topiramate extended-release capsules - VIVUS; Phentermine/CR topiramate - VIVUS; Qnexa; Qsiva; Qsymia; Topiramate/phentermine; VI-0521

Latest Information Update: 05 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VIVUS
  • Developer Alvogen; VIVUS
  • Class Amphetamines; Anorectics; Antihyperglycaemics; Dioxolanes; Hepatoprotectants; Hexoses; Ketoses; Sleep disorder therapies; Small molecules; Sulfonic acids
  • Mechanism of Action Adrenergic receptor agonists; AMPA receptor antagonists; Carbonic anhydrase inhibitors; Central nervous system stimulants; GABA A receptor agonists; Glutamate agonists; Kainic acid receptor antagonists; Neurotransmitter stimulants; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Obesity
  • Phase II Sleep apnoea syndrome; Type 2 diabetes mellitus
  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 05 Jul 2022 Phentermine/topiramate is still in clinical-Phase-Unknown development in Obesity (In adolescents, In children) in USA (PO, Controlled release)
  • 05 Jul 2022 VIVUS completes the phase III EQUIP (OB-302) trial for Obesity in the US (PO) (NCT00554216)
  • 27 Jun 2022 Efficacy data from a clinical trial in Obesity (In adolescents, In children) released by VIVUS
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top